Candel Therapeutics CADL 深 沪
已收盘 11-13 16:00:00 美东时间
6.20
-2.190
-26.10%
华盛通- 最 高6.63
- 今 开5.325
- 成交量 662.21万股
- 最 低 5.20
- 昨 收 8.39
- 总市值 4.74亿
- 52周最高 14.00
- 市盈率 静 --
- 换手率 8.65%
- 52周最低 4.35
- 委 比 -25.41%
- 总股本 7651.86万
- 历史最高 14.78
- 量 比 5.54
- 振 幅 17.04%
- 历史最低 0.66
- 每 手 1
- 风险率 2.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stifel Maintains Buy on Candel Therapeutics, Lowers Price Target to $19
Stifel analyst Stephen Willey maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $22 to $19.
11-13 21:00
Candel Therapeutics Shares Tumble 39% After-Hours: Here's Why
Candel Therapeutics Inc. (NASDAQ:CADL) shares fell 39.09% to $5.11 in after-hours trading on Thursday after the company reported a wider third-quarter loss and said it currently plans to submit its prostate cancer regulatory application in mid-2027, pending ongoing discussions with the FDA. The clin...
11-13 13:51
Candel Therapeutics Q3 EPS $(0.28) Beats $(0.35) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.35) by 20 percent. This is a 33.33 percent decrease over losses of $(0.21) per share from the same period last year.
11-13 05:32
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
Candel Therapeutics announced clinical and biomarker data from three poster presentations at the Society for Immunotherapy of Cancer’s 41st Annual Meeting, highlighting immune effects and survival outcomes for aglatimagene in localized prostate cancer and NSCLC, and for linoserpaturev in recurrent glioblastoma. Data showed systemic cytotoxic T-cell activation with aglatimagene in prostate cancer, longitudinal immune changes linked to long-term su...
11-06 14:00
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted stock options to 4 new employees under its 2025 Inducement Plan, totaling 107,600 shares with an exercise price of $8.33. The options vest over 4 years, with 25% on the first anniversary and the remaining 75% in monthly installments. The company focuses on developing multimodal immunotherapies for cancer, with lead candidates aglatimagene and linoserpaturev in clinical trials. AGLU recently completed Phase 2a trials in...
11-02 21:05
Candel Therapeutics to Present at November Investor Conferences
Candel Therapeutics' CEO, Paul Peter Tak, will participate in fireside chats at the Stifel 2026 Healthcare Conference (November 10, New York) and the Jefferies Global Healthcare Conference (November 18, London). Candel is a biopharmaceutical company developing multimodal immunotherapies for cancer, with lead candidates aglatimagene and linoserpaturev in clinical trials for prostate cancer, NSCLC, PDAC, and glioma. The company's platforms include ...
10-27 12:05
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25
Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $25.
10-23 04:31
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Candel Therapeutics appoints Maria Ostrovsky as General Counsel, bringing 20 years of legal and compliance experience in the life sciences industry. Ostrovsky will oversee the company’s legal and compliance functions as it prepares for a planned Biologics License Application (BLA) submission for aglatimagene besadenovec in prostate cancer and potential commercialization. Ostrovsky has extensive experience in global product launches, strategic tra...
10-22 12:05
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted stock options to 4 new employees for 85,900 shares at $10.44 per share under its 2025 Inducement Plan. The options vest 25% after one year and the remaining 75% over 36 months. The company focuses on developing multimodal immunotherapies for cancer, with lead candidates aglatimagene and linoserpaturev in clinical trials.
10-01 20:05
